Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-10Clinical Trial Results: Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy [Phase 1]
Phase 1 trial results of NT-I7 after CD19 CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma show early efficacy signal…
-
EMA approval · 2026-08-06EMA Authorised: Tepkinly (epcoritamab) — AbbVie Deutschland GmbH & Co. KG
EMA authorised Tepkinly (epcoritamab) for diffuse large B-cell lymphoma under conditional approval.
-
EMA approval · 2026-08-06EMA Authorised: Breyanzi (lisocabtagene maraleucel) — Bristol-Myers Squibb Pharma EEIG
The EMA has authorised Breyanzi (lisocabtagene maraleucel) for specified lymphomas, including large B-cell diffuse and follicular lymphoma, …
-
EMA approval · 2026-06-09EMA Authorised: Tepkinly (epcoritamab) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Tepkinly (epcoritamab) by AbbVie for diffuse large B-cell lymphoma, granting conditional approval.
-
EMA approval · 2026-06-08EMA Authorised: Yescarta (axicabtagene ciloleucel) — Kite Pharma EU B.V.
The EMA authorises Yescarta (axicabtagene ciloleucel) for certain lymphomas, indicating market authorization and orphan designation.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-28Clinical Trial Update: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 3]
A Phase 3 trial comparing Loncastuximab Tesirine plus Rituximab to standard immunochemotherapy in relapsed or refractory diffuse large B-cel…
-
CLINICAL_TRIALS trial_result · 2026-04-28Clinical Trial Update: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma [Phase 2, Phase 3]
Phase 2/3 clinical trial evaluating CC-486 (oral azacitidine) added to standard therapy in older adults with newly diagnosed diffuse large B…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies [Phase 1]
Phase 1 trial evaluating anti-CD22 CAR T cells in pediatric and young adult patients with recurrent or refractory CD22-expressing B-cell mal…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating mosunetuzumab in combination with chemotherapy for untreated C-MYC rearrangement-positive high-grade B…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) [Phase 2]
A Phase 2 feasibility trial of glofitamab for diffuse large B-cell lymphoma using interim FDG PET and ctDNA to optimize initial therapy; the…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the combination of epcoritamab, rituximab, gemcitabine, and oxaliplatin (R-GemOx) as salvage therapy befor…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma [Phase 2]
Phase 2 trial update on CD70 CAR NK cells for primary refractory or early-relapsed diffuse large B-cell lymphoma and Hodgkin lymphoma; the s…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 1]
A Phase 1 clinical trial is evaluating a triple-drug regimen consisting of mosunetuzumab, polatuzumab vedotin, and lenalidomide for relapsed…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) [Phase 3]
This is a Phase 3 study evaluating Zilovertamab Vedotin in combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP)…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma [EARLY_Phase 1]
Early-phase clinical trial update on the safety, efficacy and metabolic kinetics of CT1182 injection in relapsed/refractory non-Hodgkin lymp…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers [Phase 1]
Phase 1 safety study update for PF-08046044/SGN-35C in adults with advanced cancers; the trial is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma [Phase 1]
Phase 1 clinical trial evaluating mosunetuzumab consolidation after autologous stem cell transplantation in relapsed/refractory aggressive B…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy [Phase 3]
A Phase 3 trial is evaluating KITE-753 versus Axicabtagene Ciloleucel for relapsed or refractory diffuse large B-cell lymphoma after first-l…
-
CLINICAL_TRIALS trial_result · 2026-04-22Clinical Trial Update: Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment [Phase 1]
Phase 1 trial to assess the safety of the anti-cancer drugs tazemetostat and belinostat in patients with recurrent or refractory lymphomas; …
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial update on TTI-622 in combination with pembrolizumab for relapsed or refractory diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma [Phase 1]
This ClinicalTrials.gov update describes an ongoing Phase 1 study of 19(T2)28z1xx TRAC-CAR T cells in patients with B-cell lymphomas, includ…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies [Phase 1, Phase 2]
This is a Phase 1/2 dose-escalation and expansion study of BGB-16673 in patients with various B-cell malignancies and is currently recruitin…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating the effectiveness of ViPOR in relapsed/refractory aggressive B-cell lymphomas; the study includes Diffuse …
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma [Phase 2]
Phase 2 clinical trial at Beijing Tongren Hospital evaluating a CD19/CD22 bispecific CAR-T cell therapy for relapsed/refractory diffuse larg…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept [Phase 2]
Phase 2 clinical trial evaluating a glofitamab-based induction and consolidation strategy for high-risk second-line relapsed/refractory diff…